financetom
Business
financetom
/
Business
/
BMW plans to bring its first hydrogen car onto the market from 2028
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BMW plans to bring its first hydrogen car onto the market from 2028
Sep 6, 2024 12:51 PM

BERLIN (Reuters) - BMW aims to bring its first hydrogen-powered vehicle onto the market in 2028, using fuel cell technology developed with Toyota Motor Corp ( TM ), the German carmaker said on Thursday.

The company said the vehicle would be an existing model with a hydrogen fuel cell drive option, without giving further details. It also did not give details on price or production volume.

BMW CEO Oliver Zipse said in a statement the vehicle would "highlight how technological progress is shaping the mobility of the future".

Its partnership with Toyota ( TM ) will allow the groups to cut costs and to develop a passenger car drive unit whose technology will also have applications for commercial vehicles, they said.

BMW is by far the strongest proponent of hydrogen technology among German carmakers, and has been testing a hydrogen passenger vehicle, the iX5 Hydrogen, with a range of 500 km (310 miles) and an ability to refuel in three to four minutes.

The group is developing fuel cell vehicle prototypes alongside battery ones to hedge its bets depending on which "green" technology becomes dominant.

A fuel cell vehicle uses an electric motor like an EV, but draws power from a fuel stack where hydrogen is separated by a catalyst to produce electricity.

Hydrogen-powered vehicles can refuel quickly and have a long range, but few carmakers have invested in the technology because of high costs and a limited network of fuelling stations.

BMW said it assumed hydrogen charging infrastructure would have developed significantly by 2028 to accommodate its plans.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels
Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels
Apr 2, 2024
April 2 (Reuters) - Verve Therapeutics ( VERV ) said on Tuesday that it had paused enrollment for an early-stage study testing its experimental gene editing therapy for high cholesterol after a patient experienced a severe drug-related adverse event. The company was testing the therapy in patients with a genetic condition that leads to high cholesterol levels, which raises the...
Amazon offers free credits for startups to use AI models including Anthropic
Amazon offers free credits for startups to use AI models including Anthropic
Apr 2, 2024
(Reuters) - Amazon Web Service (AWS) has expanded its free credits program for startups to cover the costs of using major AI models, the company told Reuters in an interview, as it looks to boost the market share of its AI platform Bedrock. In a move to attract startup customers, Amazon ( AMZN ) now allows its cloud credits to...
China's Huawei Investment plans $10.7 billion in dividends
China's Huawei Investment plans $10.7 billion in dividends
Apr 2, 2024
BEIJING (Reuters) - China's Huawei Investment & Holding Co intends to distribute shareholder dividends amounting to 77.095 billion yuan ($10.65 billion), the Shanghai clearing house said on Tuesday without elaborating. ($1 = 7.2359 Chinese yuan renminbi) ...
Roivant's anti-inflammatory drug succeeds in mid-stage study
Roivant's anti-inflammatory drug succeeds in mid-stage study
Apr 2, 2024
By Bhanvi Satija April 2 (Reuters) - Roivant Sciences ( ROIV ) said on Tuesday its experimental drug to treat non-infectious uveitis helped reduce symptoms of the inflammatory eye disease in a mid-stage study. In the study testing 26 patients, 29% of those who received a higher-strength 45 milligram (mg) dose and 44% of those who received a 15 mg...
Copyright 2023-2026 - www.financetom.com All Rights Reserved